PRESS RELEASES

Date	Title
Aug 9, 2017	Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results
Aug 2, 2017	Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
May 12, 2017	Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 5, 2017	Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
Apr 18, 2017	Ardelyx To Present at Upcoming Spring Medical Meetings
Feb 27, 2017	Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
Feb 17, 2017	Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
Feb 15, 2017	Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
Jan 3, 2017	Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
Jan 3, 2017	Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com